Next Article in Journal
Salivary Gland Function, Antioxidant Defence and Oxidative Damage in the Saliva of Patients with Breast Cancer: Does the BRCA1 Mutation Disturb the Salivary Redox Profile?
Previous Article in Journal
Implementation of the Chick Chorioallantoic Membrane (CAM) Model in Radiation Biology and Experimental Radiation Oncology Research
Open AccessReview

Health-Related Quality of Life in Adrenocortical Carcinoma

Department of Internal Medicine, Máxima MC, 5631 Eindhoven/Veldhoven, The Netherlands
CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht University, 6200 Maastricht, The Netherlands
Department of Internal Medicine, Division of General Internal Medicine, Maastricht University Medical Centre+, 6229 Maastricht, The Netherlands
Author to whom correspondence should be addressed.
Cancers 2019, 11(10), 1500;
Received: 4 September 2019 / Revised: 26 September 2019 / Accepted: 4 October 2019 / Published: 8 October 2019
(This article belongs to the Special Issue Adrenocortical Carcinoma)
Insight into the health-related quality of life (HRQoL) impact of adrenocortical carcinoma (ACC) is important. The disease and its treatment options potentially have an impact on HRQoL. For patients with limited survival, HRQoL research is of utmost importance. We will therefore provide an overview of HRQoL studies in patients with ACC. We found six studies that measured HRQoL in 323 patients with ACC (3 cross-sectional, 1 cohort, 2 trials), all indicating a reduced HRQoL compared to the general population. The FIRMACT trial found that HRQoL of patients with ACC was reduced compared to the general population, and that chemotherapy-mitotane further reduced HRQoL even though survival improved. Clinical aspects of the disease, including cortisol and aldosterone production and adrenal insufficiency have shown great impact on HRQoL in benign disease, even after the recovery of hormonal status. However, the impact of malignant adrenal disease and treatment options on HRQoL including adrenalectomy, radiotherapy, mitotane therapy, and chemotherapy have not been sufficiently studied in patients with ACC. Although the number of HRQoL studies in patients with ACC is limited, the existing literature does indicate that ACC has a large impact on patients’ HRQoL, with disease specific aspects. Further HRQoL research in patients with ACC is essential to improve patient-centered care, preferably by using an ACC-specific HRQoL questionnaire. View Full-Text
Keywords: adrenocortical carcinoma; health-related quality of life; adrenalectomy; mitotane; chemotherapy adrenocortical carcinoma; health-related quality of life; adrenalectomy; mitotane; chemotherapy
Show Figures

Figure 1

MDPI and ACS Style

Steenaard, R.V.; Michon, L.A.; Haak, H.R. Health-Related Quality of Life in Adrenocortical Carcinoma. Cancers 2019, 11, 1500.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop